The handle http://hdl.handle.net/1887/50091 holds various files of this Leiden University dissertation

**Author:** Doorduijn, Elien  
**Title:** T cell immunity against MHC-I low tumors in mouse models  
**Issue Date:** 2017-06-29
1. TEIPP T cells are an ideal platform for the treatment of TAP-deficient tumors due to their efficient thymic selection, their effective activation upon peptide vaccination and their specific recognition of TAP-deficient cells (*this thesis*).

2. The lack of TEIPP T cell activation in mice bearing a MHC-I$_{\text{low}}$ tumor can be explained by direct priming, requiring high levels of both MHC-I and antigen, being the major pathway of TEIPP T cell activation (*this thesis*).

3. The Trh4 peptide acquires a unique conformation with the H2-D$^b$ molecule, which is essential for T cell recognition (*this thesis*).

4. The size of an intratumoral immune cell population does not always reflect the importance of that particular population for immune mediated control of tumor growth (*this thesis*).

5. Characterization of the molecular mechanism underlying the lack or downregulation of HLA class I expression, seems to be a crucial step predicting clinical responses to T cell mediated immunotherapy. This will aid the selection of strategies that could condition patients for response. (Thor Straten P and Garrido F, *J Immunother Cancer* (2016)).

6. When targeting a suitable epitope, the levels of MHC-I may not be as an important factor for cancer eradication as previously believed, which is encouraging considering that many tumors express low levels of MHC-I (Textor et al., *Journal of Experimental Medicine* (2016)).

7. Loss of IFN-γ signaling in tumor cells may represent a common mechanism for tumor resistance to immune checkpoint therapy. As a result, MHC-I levels are strongly reduced in these tumors, urging the need to identify novel strategies to target these MHC-I$_{\text{low}}$ tumors (based on Gao et al., *Cell* (2016) and Zaretsky et al., *New England Journal of Medicine* (2016)).

8. Ultimately, innate immune pathway agonists might promote *de novo* activation and recruitment of anti-tumor T cells, which still may become held in check by negative regulatory pathways such as PD-1/PD-L1 interactions (Corrales et al., *Cell Research* (2017)).

9. De wetenschap moet beter communiceren naar t algemene publiek

10. Life at its best is an adventure, a voyage of discovery (Peter Doherty, *The beginner’s guide to winning the Nobel Prize, advice for young scientists* (2008)).

11. Compromissen zijn soms nodig om iets te bereiken. Met je hakken in het zand is het lastig lopen (Loesje)